🇮🇳IN
Sign In
AU

AUROPHARMA

NSE

Aurobindo Pharma Ltd

₹1,571.70

-39.20(-2.43%)
FSI

Fundamental Strength Index

computed from the statements below↑ higher is better

Weights come from configuration, not from this page — each pillar links to the section below that explains it.

Income stmtHistory

Profitability

headline ratios

Growth

compounded, from filed annual results

Segment Results

₹ Cr

Working Capital & Efficiency

days · ROCE %

AUROPHARMA financial summary

For Mar 2026, Aurobindo Pharma Ltd reported revenue of ₹11,172 crore, which grew 2.2% from the previous year. Net profit was ₹2,415 crore, which grew 38.2% year on year, on an operating margin of 28%. Earnings per share came in at ₹41.58. Annual results are available for 14 financial years, from Mar 2013 to Mar 2026.

Revenue₹11,172 crore
Net profit₹2,415 crore
Operating margin28%
EPS₹41.58

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer